NCT07532135 Safety of Mulberry Leaf Extract Capsule on Blood Glucose Control in Healthy Volunteer
| NCT ID | NCT07532135 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Chulalongkorn University |
| Condition | Healthy Volunteers |
| Study Type | INTERVENTIONAL |
| Enrollment | 48 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 48 participants in total. It began in 2025-10-01 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Volunteers were divided into 2 groups: mulberry leaf extract capsule (DNJ 12mg) group and placebo group. They took the sample 3 times/day for 8 weeks. Complete blood count, Blood urea nitrogen (BUN), Creatinine, Aspartate transaminase (AST), Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Fasting plasma glucose, HbA1c, and adverse effects were evaluated before and after 4 and 8 weeks.
Eligibility Criteria
Inclusion Criteria: * Male or female age more than 18 years * No Diabetis mellitus disease and no taking diabetes medication * Blood sugar level less than 126 mg/dl and HbA1C less than 6.5 * Can using Thai language * Willing to participate in the study Exclusion Criteria: * Allergic to mulberry extract * Take mulberry extract in 2 weeks before participate in this study * Take medications that have effect on blood sugar level such as steroid in 2 weeks before participate in this study * Have uncontrolled disease * Have AST, ALT, ALP more than 3 times of normal value, or estimated Glomerular Filtration Rate less than 30 ml/min/1.73 m2) * Pregnancy or lactation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07532135 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Healthy Volunteers. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07532135 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07532135 currently recruiting?
Yes, NCT07532135 is actively recruiting participants. Contact the research team at aramwit@gmail.com for enrollment information.
Where is the NCT07532135 trial being conducted?
This trial is being conducted at Bangkok, Thailand.
Who is sponsoring the NCT07532135 clinical trial?
NCT07532135 is sponsored by Chulalongkorn University. The trial plans to enroll 48 participants.